Item 5.02. Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 15, 2022, the Board of Directors (the "Board") of Cowen Inc. (the "Company") appointed Lorence Kim, M.D., to serve on the Company's Board of Directors, effective immediately. Dr. Kim's appointment expands the Board to nine directors.

Dr. Kim is currently a Venture Partner at Third Rock Ventures. Until June 2020, he served as Chief Financial Officer of Moderna, leading efforts to raise $4.4 billion of capital. At the time of his departure, Moderna had raised the three largest private financing rounds and the largest IPO in biotech history. Dr. Kim joined Moderna after spending 14 years at Goldman Sachs, most recently as a Managing Director and co-head of the U.S. biotechnology investment banking effort.

Dr. Kim graduated magna cum laude from Harvard University with a bachelor's degree in biochemical sciences. He earned an M.B.A. in healthcare management as a Palmer Scholar from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine.

Dr. Kim currently serves as a member of the Boards of Directors of Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, and Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, and on the Board of Governors of the American Red Cross. He previously served on the Board of Seres Therapeutics.

On February 15, 2022, the Company issued a press release announcing the appointment of Dr. Kim. A copy of the press release is attached hereto at Exhibit 99.1.

--------------------------------------------------------------------------------




 Item 9.01. Financial Statements and Exhibits.
(d)             Exhibit

  99.1            Press Release issued by the Company dated February 15, 2022.







--------------------------------------------------------------------------------

© Edgar Online, source Glimpses